Table 5

Patient characteristics and OS (univariate analysis)

CharacteristicsNo. of patients (N = 102)Hazard ratio95% CIP
Age* — 1.33† 1.07, 1.65 .010 
Gender    .505 
 Female‡ 54    
 Male 48 1.20 0.70, 2.05  
Total number of prior systemic therapy regimens* — 1.12 1.01, 1.24 .026 
Best response achieved with most recent regimen    .537 
 Objective response‡ 47    
 Stable disease 23 0.86 0.43, 1.71  
 Progressive disease 26 1.34 0.7, 2.58  
 Unknown/other 6 0.55 0.13, 2.31  
Any prior cancer-related radiotherapy    .975 
 Yes‡ 67    
 No 35 1.01 0.58, 1.76  
Time from initial diagnosis to first dose (months)* — 1.00 0.99, 1.00 .406 
Time since diagnosis (months)/total no. of systemic therapies* — 1.02 0.99, 1.06 .233 
Time from last auto-SCT to relapse prior to b-v (months)* — 1.00 0.98, 1.01 .694 
PFS from prior cancer therapy (months)* — 0.99 0.97, 1.01 .455 
Stage at initial diagnosis,§n (%)    .094 
 Stage I/II‡ 51    
 Stage III 27 1.64 0.84, 3.19  
 Stage IV 20 2.04 1.04, 4.01  
Baseline ECOG performance status    .004 
 Grade 0‡ 42    
 Grade 1 60 2.37 1.32, 4.26  
Baseline electrocardiogram    .423 
 Normal‡ 60    
 Abnormal 42 1.25 0.73, 2.14  
Baseline SPD per investigator (cm2)* — 1.04|| 1.00, 1.08 .033 
Baseline soluble CD30 (ng/mL)* — 1.00 1.00, 1.00 .025 
Primary refractory status    .931 
 No‡ 30    
 Yes 72 0.97 0.55, 1.73  
Disease status relative to most recent prior therapy    .089 
 Refractory‡ 43    
 Relapse 59 0.63 0.37, 1.07  
Baseline B symptoms    .662 
 No‡ 67    
 Yes 35 1.13 0.65, 1.97  
CharacteristicsNo. of patients (N = 102)Hazard ratio95% CIP
Age* — 1.33† 1.07, 1.65 .010 
Gender    .505 
 Female‡ 54    
 Male 48 1.20 0.70, 2.05  
Total number of prior systemic therapy regimens* — 1.12 1.01, 1.24 .026 
Best response achieved with most recent regimen    .537 
 Objective response‡ 47    
 Stable disease 23 0.86 0.43, 1.71  
 Progressive disease 26 1.34 0.7, 2.58  
 Unknown/other 6 0.55 0.13, 2.31  
Any prior cancer-related radiotherapy    .975 
 Yes‡ 67    
 No 35 1.01 0.58, 1.76  
Time from initial diagnosis to first dose (months)* — 1.00 0.99, 1.00 .406 
Time since diagnosis (months)/total no. of systemic therapies* — 1.02 0.99, 1.06 .233 
Time from last auto-SCT to relapse prior to b-v (months)* — 1.00 0.98, 1.01 .694 
PFS from prior cancer therapy (months)* — 0.99 0.97, 1.01 .455 
Stage at initial diagnosis,§n (%)    .094 
 Stage I/II‡ 51    
 Stage III 27 1.64 0.84, 3.19  
 Stage IV 20 2.04 1.04, 4.01  
Baseline ECOG performance status    .004 
 Grade 0‡ 42    
 Grade 1 60 2.37 1.32, 4.26  
Baseline electrocardiogram    .423 
 Normal‡ 60    
 Abnormal 42 1.25 0.73, 2.14  
Baseline SPD per investigator (cm2)* — 1.04|| 1.00, 1.08 .033 
Baseline soluble CD30 (ng/mL)* — 1.00 1.00, 1.00 .025 
Primary refractory status    .931 
 No‡ 30    
 Yes 72 0.97 0.55, 1.73  
Disease status relative to most recent prior therapy    .089 
 Refractory‡ 43    
 Relapse 59 0.63 0.37, 1.07  
Baseline B symptoms    .662 
 No‡ 67    
 Yes 35 1.13 0.65, 1.97  

Significant factors in the univariate analysis are indicated in italic font.

b-v, brentuximab vedotin.

*

Continuous variable.

†

Hazard ratio applies to 10-year increments.

‡

Reference level for the hazard ratio.

§

Stage was unknown for 4 patients.

||

Hazard ratio applies to 10-cm2 increments.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal